Clayton Yates to Antineoplastic Agents
This is a "connection" page, showing publications Clayton Yates has written about Antineoplastic Agents.
Connection Strength
0.416
-
Yates C, Sharp S, Jones J, Topps D, Coleman M, Aneja R, Jaynes J, Turner T. LHRH-conjugated lytic peptides directly target prostate cancer cells. Biochem Pharmacol. 2011 Jan 01; 81(1):104-10.
Score: 0.219
-
Arora R, Yates C, Gary BD, McClellan S, Tan M, Xi Y, Reed E, Piazza GA, Owen LB, Dean-Colomb W. Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer. PLoS One. 2014; 9(6):e98370.
Score: 0.071
-
Wang H, Jones J, Turner T, He QP, Hardy S, Grizzle WE, Welch DR, Yates C. Clinical and biological significance of KISS1 expression in prostate cancer. Am J Pathol. 2012 Mar; 180(3):1170-1178.
Score: 0.060
-
Abdalla MO, Karna P, Sajja HK, Mao H, Yates C, Turner T, Aneja R. Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy. J Control Release. 2011 Feb 10; 149(3):314-22.
Score: 0.055
-
Aneja R, Liu M, Yates C, Gao J, Dong X, Zhou B, Vangapandu SN, Zhou J, Joshi HC. Multidrug resistance-associated protein-overexpressing teniposide-resistant human lymphomas undergo apoptosis by a tubulin-binding agent. Cancer Res. 2008 Mar 01; 68(5):1495-503.
Score: 0.011